Endometrial Stromal Sarcoma
Symptoms, Doctors, Treatments, Advances & More

Endometrial Stromal Sarcoma Overview

Save information for later
Sign Up

Learn About Endometrial Stromal Sarcoma

What is the definition of Endometrial Stromal Sarcoma?
Endometrial stromal sarcoma is a rare form of cancer that occurs due to abnormal and uncontrolled cell growth in the uterus. Endometrial stromal sarcoma, specifically, develops in the supporting connective tissue (stroma) of the uterus. Signs and symptoms of the condition include abnormal uterine bleeding (i.e. bleeding that is not part of menstrual periods or bleeding after menopause); abdominal pain and/or distension; and frequent urination. The exact underlying cause of Endometrial stromal sarcoma is currently unknown. Most cases occur sporadically in people with no family history of the condition.
What are the alternative names for Endometrial Stromal Sarcoma?
  • Endometrial stromal sarcoma
  • ESS
Who are the top Endometrial Stromal Sarcoma Local Doctors?
Distinguished in Endometrial Stromal Sarcoma
Dr. Scott Kamelle
Oncology
Distinguished in Endometrial Stromal Sarcoma
Dr. Scott Kamelle
Oncology

Aurora Gynecologic Oncology

8905 W Lincoln Ave, Ste 407, 
West Allis, WI 
414-329-5656
Languages Spoken:
English
See accepted insurances

Scott Kamelle is an Oncologist practicing medicine in West Allis, Wisconsin. Dr. Kamelle is rated as a Distinguished provider by MediFind in the treatment of Endometrial Stromal Sarcoma. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Ureteroscopy, and Bladder Reconstruction. Dr. Kamelle is board certified in American Board Of Obstetrics & Gynecology, Gynecologic Oncology.

Elite in Endometrial Stromal Sarcoma
Dr. Mario Leitao
Gynecologic Oncology | Oncology
Elite in Endometrial Stromal Sarcoma
Dr. Mario Leitao
Gynecologic Oncology | Oncology

Rockefeller Outpatient Pavilion

160 E 53rd St, 
New York, NY 
914-229-2473
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mario Leitao is a Gynecologic Oncologist and an Oncologist practicing medicine in New York, New York. Dr. Leitao is rated as an Elite provider by MediFind in the treatment of Endometrial Stromal Sarcoma. He is also highly rated in 21 other conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Vulvar Cancer, Vaginal Cancer, Hysterectomy, and Lymphadenectomy. Dr. Leitao is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Distinguished in Endometrial Stromal Sarcoma
Dr. John B. Villeneuve
Oncology | Obstetrics and Gynecology
Distinguished in Endometrial Stromal Sarcoma
Dr. John B. Villeneuve
Oncology | Obstetrics and Gynecology

Tower Health Medical Group Gynecologic Oncology - West Reading

420 S 5th Avenue, Bldg N, 
West Reading, PA 
484-628-8905
Languages Spoken:
English
See accepted insurances

. Dr. Villeneuve is rated as a Distinguished provider by MediFind in the treatment of Endometrial Stromal Sarcoma. He is also highly rated in 21 other conditions, according to our data. His clinical expertise encompasses Vulvar Cancer, Endometrial Cancer, Endometrial Stromal Sarcoma, Bladder Reconstruction, and Hysterectomy. Dr. Villeneuve is board certified in American Board Of Obstetrics And Gynecology.

View All Doctors
What are the latest Endometrial Stromal Sarcoma Clinical Trials?
Randomized Comparative Prospective Multicentre Phase II Trial Evaluating Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic LGESS
Randomized Comparative Prospective Multicentre Phase II Trial Evaluating Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic LGESS
Who is this study for: Patients with Low Grade Endometrial Stromal Sarcoma
Enrollment Status: Recruiting
Publish Date: February 17, 2026
Intervention Type: Drug
Study Drug: Aromatase Inhibitors
Study Phase: Phase 2

Summary: The primary objective is to compare the progression-free survival (PFS) between aromatase inhibitors interruption and aromatase inhibitors maintenance strategies in patients with a locally advanced or metastatic Low Grade Endometrial Stromal Sarcoma (LGESS).

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase II Study Evaluating the Safety and Efficacy of MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment in Patients With Advanced Soft Tissue Sarcoma
A Phase II Study Evaluating the Safety and Efficacy of MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment in Patients With Advanced Soft Tissue Sarcoma
Enrollment Status: Recruiting
Publish Date: July 24, 2025
Intervention Type: Drug, Biological
Study Phase: Phase 2

Summary: This study will evaluate the safety and efficacy of MASCT-I combined with Doxorubicin and Ifosfamide for first-line treatment in patients with advanced soft tissue sarcoma.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center